J&J
J&J seek approval for first drug to treat high-risk smoldering myeloma
November 13, 2024Research and Development FDA, J&J, Rare Diseases, bone marrow
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and Drug Agency (FDA) and the …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
July 24, 2024Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
May 21, 2024Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
April 29, 2024Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn
March 11, 2024Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …
J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
February 12, 2024Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …
J&J’s to submit surgical robot to FDA in 2024
November 8, 2023Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot
Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …
FDA approved Janssen’s Akeega for prostate cancer treatment
August 14, 2023Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer
The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
New warning added to J&J vaccine in US
July 13, 2021Manufacturing and Production COVID-19, FDA, J&J, JJ, US, Vaccine
The FDA has made the decision to add a warning to the fact sheet for Johnson & Johnson’s COVID-19 vaccine, …
J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis
June 4, 2021Medical Communications J&J, JJ
Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …
J&J COVID-19 vaccine to resume Europe rollout
April 21, 2021Research and Development COVID-19, COVID-19 vaccine, J&J, J&J vaccine, JJ, pharma, pharma news
The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review from the EMA.
EMA launch investigation into J&J’s COVID-19 vaccine amid US blood clot reports
April 12, 2021Sales and Marketing COVID-19, EMA, J&J, JJ, Vaccine
The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s …
Latest content
